{Reference Type}: Journal Article
{Title}: Invasive Coronary Imaging Assessment for Cardiac Allograft Vasculopathy: State-of-the-Art Review.
{Author}: Shahandeh N;Kashiyama K;Honda Y;Nsair A;Ali ZA;Tobis JM;Fearon WF;Parikh RV;
{Journal}: J Soc Cardiovasc Angiogr Interv
{Volume}: 1
{Issue}: 4
{Year}: 2022 Jul-Aug
暂无{DOI}: 10.1016/j.jscai.2022.100344
{Abstract}: Heart transplantation is the standard of care treatment for end-stage heart failure. Therapeutic advances including enhanced immunosuppression and aggressive infectious prophylaxis have led to increased life-expectancy following transplantation; however, cardiac allograft vasculopathy (CAV) remains a leading cause of morbidity and mortality. Although coronary angiography is the current guideline-recommended diagnostic modality for invasive CAV screening, it is limited in its ability to detect early and/or diffuse disease. Efforts to improve outcomes for heart transplant recipients with CAV have focused on developing diagnostic tools with greater sensitivity to capture early CAV in order to better understand the pathobiology and implement treatment to slow disease progression sooner after transplant. The contemporary invasive imaging armamentarium for CAV surveillance includes coronary angiography, intravascular ultrasound, and newer technologies including optical coherence tomography and near-infrared spectroscopy. The present review outlines the use of and data in support of these imaging platforms in the CAV arena and highlights the potential advantages and limitations of each of these modalities.